Drug Profile
Prohibitin targeting peptide 1
Alternative Names: Adipotide; Prohibitin-TP01Latest Information Update: 18 Jan 2019
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Ablaris Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Obesity therapies; Peptides; Peptidomimetics
- Mechanism of Action Apoptosis stimulants; Prohibitin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 18 Jan 2019 Discontinued - Phase-I for Obesity in USA (SC)
- 02 Jan 2019 Ablaris Therapeutics terminates the phase I FatZapper trial in Obesity in USA as per principal investigators request (SC) (NCT01262664)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)